Cargando…

Analysis of Cancer Survival Associated With Immune Checkpoint Inhibitors After Statistical Adjustment: A Systematic Review and Meta-analyses

IMPORTANCE: Appropriate clinical decision-making relies on accurate data interpretation, which in turn relies on the use of suitable statistical models. Long tails and early crossover—2 features commonly observed in immune checkpoint inhibitor (ICI) survival curves—raise questions as to the suitabil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Emily Pei-Ying, Hsu, Chih-Yuan, Berry, Lynne, Bunn, Paul, Shyr, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386543/ https://www.ncbi.nlm.nih.gov/pubmed/35976648 http://dx.doi.org/10.1001/jamanetworkopen.2022.27211

Ejemplares similares

Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy
por: Van Buren, Inga, et al.
Publicado: (2023)

Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
por: Wang, Zi-Xian, et al.
Publicado: (2019)

Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors
por: Bomze, David, et al.
Publicado: (2020)

Associations of influenza vaccination with severity of immune-related adverse events in patients with advanced thoracic cancers on immune checkpoint inhibitors
por: Lin, Emily Pei-Ying, et al.
Publicado: (2022)

Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis
por: Kok, Peey-Sei, et al.
Publicado: (2020)

Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non–Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale
por: Everest, Louis, et al.
Publicado: (2019)

Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis
por: Jácome, Alexandre A., et al.
Publicado: (2021)

Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events: A Systematic Review and Meta-analysis
por: Farooq, Muhammad Zain, et al.
Publicado: (2022)

Rapamycin and hydroxychloroquine combination alters macrophage polarization and sensitizes glioblastoma to immune checkpoint inhibitors
por: Hsu, Sanford P. C., et al.
Publicado: (2020)

Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis
por: Chang, Ching-Yuan, et al.
Publicado: (2020)

Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma
por: Jang, Se Ryeong, et al.
Publicado: (2021)

Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal Cancer
por: Zhuo, Na, et al.
Publicado: (2022)

Reproduction and In-Depth Evaluation of Genome-Wide Association Studies and Genome-Wide Meta-analyses Using Summary Statistics
por: Niu, Yao-Fang, et al.
Publicado: (2017)

Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
por: Xie, Enrui, et al.
Publicado: (2023)

Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti–PD-1 Era
por: Lamba, Nayan, et al.
Publicado: (2022)

Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults
por: Schonfeld, Sara J., et al.
Publicado: (2022)

Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors
por: Zhang, Lei, et al.
Publicado: (2020)

Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma
por: Akturk, Halis Kaan, et al.
Publicado: (2022)

Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
por: Park, Hyo Jung, et al.
Publicado: (2021)

Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials: A Systematic Review and Meta-analysis
por: Pala, Laura, et al.
Publicado: (2022)

Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor–Induced Inflammatory Arthritis
por: Subedi, Ananta, et al.
Publicado: (2020)

Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors
por: Hsiehchen, David, et al.
Publicado: (2019)

Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2020)

Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma: A Meta-analysis Including Low PD-L1 Subgroups
por: Yap, Dominic Wei Ting, et al.
Publicado: (2022)

Association Between Body Mass Index and Survival Outcomes In Patients Treated With Immune Checkpoint Inhibitors: Meta-analyses of Individual Patient Data
por: Nie, Run-Cong, et al.
Publicado: (2021)

Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors
por: Mantia, Charlene M., et al.
Publicado: (2021)

Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non−Small Cell Lung Cancer
por: Kawachi, Hayato, et al.
Publicado: (2023)

Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors
por: Msaouel, Pavlos, et al.
Publicado: (2021)

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer
por: Graf, Ryon P., et al.
Publicado: (2022)

Tumor mutation burden predicts response and survival to immune checkpoint inhibitors: a meta-analysis
por: Wan, Linghong, et al.
Publicado: (2020)

Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor–Induced Interstitial Lung Disease Among Patients With Nonlung Cancers
por: Shimoji, Kiyofumi, et al.
Publicado: (2020)

Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors
por: Waninger, Jessica J., et al.
Publicado: (2021)

Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non–Small Cell Lung Cancer
por: Kehl, Kenneth L., et al.
Publicado: (2021)

Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
por: Xu, Cheng, et al.
Publicado: (2018)

Identification of Potential Immune Checkpoint Inhibitor Targets in Gliomas via Bioinformatic Analyses
por: Ding, Mengmeng, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors and Survival Outcomes in Brain Metastasis: A Time Series-Based Meta-Analysis
por: Hu, Xingjiang, et al.
Publicado: (2020)

Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma
por: Krebs, Franziska K., et al.
Publicado: (2021)

Immune checkpoint inhibitors
por: Hui, Enfu
Publicado: (2019)

Immune checkpoint inhibitors
por: Kroemer, Guido, et al.
Publicado: (2021)

Assessment of Treatment Effects and Long-term Benefits in Immune Checkpoint Inhibitor Trials Using the Flexible Parametric Cure Model: A Systematic Review
por: Filleron, Thomas, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kjjlhagp7l565qr29suln2hfv9